Takeda picked up IBI363 for $1.2bn, and now Innovent advances IBI3026.
ApexOnco Front Page
Recent articles
And the company believes it won’t need to carry out another trial.
The recently unveiled conjugate DS3610a is to start phase 1.
After menin, the company tries again with farnesyl transferase.
The company is to start a pivotal Chinese trial of its PD-1 x TGF-β-targeting fusion protein.
The Rainfol-03 trial, in second-line endometrial cancer, builds on recent early data.
The companies clash over survival curve similarities – and differences.
After ZW171's exit, ZW251 enters the clinic.
